Genome-wide analysis of the human p53 transcriptional network unveils a lncRNA tumour suppressor signature

Yolanda Sánchez, Victor Segura, Oskar Marín-Béjar, Alejandro Athie, Francesco P. Marchese, Jovanna González, Luis Bujanda, Shuling Guo, Ander Matheu and Maite Huarte ()
Additional contact information
Yolanda Sánchez: Center for Applied Medical Research, University of Navarra
Victor Segura: Center for Applied Medical Research, University of Navarra
Oskar Marín-Béjar: Center for Applied Medical Research, University of Navarra
Alejandro Athie: Center for Applied Medical Research, University of Navarra
Francesco P. Marchese: Center for Applied Medical Research, University of Navarra
Jovanna González: Center for Applied Medical Research, University of Navarra
Luis Bujanda: Donostia Hospital—Biodonostia Research Institute, University of Basque Country (UPV/EHU), Biomedical Research Center in the Network of Digestive and Hepatic Diseases (CIBERehd), Dr Begiristain Square
Shuling Guo: Isis Pharmaceuticals
Ander Matheu: Neuro-Oncology Section, Biodonostia Research Institute, Dr Begiristain Square
Maite Huarte: Center for Applied Medical Research, University of Navarra

Nature Communications, 2014, vol. 5, issue 1, 1-13

Abstract: Abstract Despite the inarguable relevance of p53 in cancer, genome-wide studies relating endogenous p53 activity to the expression of lncRNAs in human cells are still missing. Here, by integrating RNA-seq with p53 ChIP-seq analyses of a human cancer cell line under DNA damage, we define a high-confidence set of 18 lncRNAs that are p53 transcriptional targets. We demonstrate that two of the p53-regulated lncRNAs are required for the efficient binding of p53 to some of its target genes, modulating the p53 transcriptional network and contributing to apoptosis induction by DNA damage. We also show that the expression of p53-lncRNAs is lowered in colorectal cancer samples, constituting a tumour suppressor signature with high diagnostic power. Thus, p53-regulated lncRNAs establish a positive regulatory feedback loop that enhances p53 tumour suppressor activity. Furthermore, the signature defined by p53-regulated lncRNAs supports their potential use in the clinic as biomarkers and therapeutic targets.

Date: 2014
References: Add references at CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://www.nature.com/articles/ncomms6812 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:5:y:2014:i:1:d:10.1038_ncomms6812

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms6812

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().